Page 128 - Haematologica3

M.L. Nijland et al.
Much less is known about the development of T-cell
non-Hodgkin lymphomas (T-NHL) in patients with immunodeficiencies or autoimmune diseases. For HIV patients and solid organ transplant recipients some large
case series and reviews on T-NHL have been published.14- 20 In IBD patients, the development of a specific and rare subtype of T-NHL, hepatosplenic T-NHL (HSTCL), has been associated with the use of thiopurines, either alone
Table 2. Patient and lymphoma characteristics, ordered by primary disorder.
Disorder
Number of cases
Median age Dx (y [IQR]) Sex
Male
Female
IS therapy
or chemotherapy
Median interval start drugs – Dx (m [IQR]) Duration of IST or
CT (treatment longest given)
Histologic subtype
AI disease
Total: 14
CD: 7 (50%) RA: 3 (21.4%) Sarcoidosis: 1
(7.1%)
PR: 1 (7.1 %)
M. Sjogren: 1 (7.1%) PSC: 1 (7.1%)
43 (33-53)
10 (71.4%)
4 (28.6%)
IST: 13 (92.9%) NR: 1 (7.1%)
44 (13-173)
3-6 m:-
6-12 m:1 (7.1%)
1-2 y: 3 (21.4%)
>2 y: 8 (57.1%)
NR: 2 (14.3%)
CTCL: 3 (21.4%)
AITL: 3 (21.4%)
PTCL, NOS: 2 (14.3%) Prec T-LBL: 2 (14.3%) ALCL, ALK+ : 1 (7.1%) ENKL: 1 (7.1%) HSTCL: 1 (7.1%) ALCL, ALK-: 1 (7.1%)
Hematologic malignancy
Total: 6
B-CLL: 4 (66.7%) MCL: 1 (16.7%) MM: 1 (16.7%)
75 (61-79) 6 (100%)
CT: 5 (83.3%) NR:1 (16.7%)
92 (17-154)
3-6m:-
6-12 m: 2 (33.3%)
1-2 y: 1 (16.7%)
>2 y: 1 (16.7%)
NR: 2 (33.3%)
PTCL, NOS: 3 (50%) CTCL: 1 (16.7%) ALCL, ALK-: 1 (16.7%) T-PLL : 1 (16.7%
Solid organ Tx
Total: 4
Kidney: 3 (75%) Liver: 1 (25%)
71 (52-76)
3 (75%)
1 (25%)
IS: 4 (100%)
205 (27.5-354)
3-6 m: 1 (25%) 6-12 m: - 1-2y:-
>2 y: 3 (75%) NR: -
PTCL, NOS: 1 (25%) T-NHL, unclass: 1 (25 %) ALCL, ALK-: 1 (25%) Clonal T-cell population
in liquor: 1 (25%)
HIV
Total: 1
26
1 (100%)
Total
25
52 (40-73)
20 (80%)
5 (20%)
IST: 17 (68%) CT: 5 (20%) No IST: 1 (4%) NR:2(8
76 (14,3-171)
3-6 m: 1 (4%) 6-12 m: 3 (12%) 1-2 y: 4 (16%) >2 y: 12 (48%) NR: 4 (16%) PTCL, NOS:
6 (24%) ALCL, ALK-:
4 (16%)
AITL:3 (12%) CTCL: 4 (16%) Prec T-LBL:
2 (8%)
ALCL, ALK+ :
1 (4%)
ENKL: 1 (4%) HSTCL: 1 (4%) T-PLL: 1 (4%) Clonal T cell population in liquor: 1 (4%) T-NHL, unclass: 1 (4%)
LN: 9 (36%) EN: 23 (92%) Exclusive EN:
16 (64%)
-
-
No IS: 1(100%)
- -
ALCL, ALK-: 1 (100 %)
Location
LN: 5 (35.7%)
EN: 13 (92.9%) Exclusive EN: 9 (64.2%)
LN: 3 (50%)
EN: 5 (83.3%) Exclusive EN: 3 (50%)
LN: 1 (25%)
EN: 4 (100%) Exclusive EN: 3 (75%)
LN: -
EN: 1 (100%) Exclusive EN: 1 (100%)
488
continued in the next page
haematologica | 2018; 103(3)